Publicaciones científicas

¿Necesita concretar más?
/cun/investigacion/publicaciones-cientificas/areaMain/02

  • 5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging

    Martínez-Terroba E (1,2), Behrens C (3), Agorreta J (1,2,4,5), Monsó E (6,7), Millares L (6,7), Felip E (8), Rosell R (9), Ramirez JL (9), Remirez A (1), Torre W (4,10), Gil-Bazo I (1,4,5,11), Idoate MA (2,4,5,12), de-Torres JP (4,5,13), Pio R (1,4,5,14), Wistuba II (3,15), Pajares MJ (1,2,4,5), Montuenga LM (1,2,4,5).

    (1) Program in Solid Tumors, CIMA, Pamplona, Spain.
    (2) Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain.
    (3) Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
    (4) Navarra Health Research Institute (IDISNA), Pamplona, Spain.
    (5) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
    (6) Neumology Service, Parc Taulí Universitary Hospital, Sabadell, Spain.
    (7) CIBER de Enfermedades Respiratorias-CIBERES, Instituto de Salud Carlos III, Madrid, Spain.
    (8) Vall d'Hebron University Hospital, Institute of Oncology, Barcelona, Spain.
    (9) Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.
    (10) Department of Thoracic Surgery, Clínica Universidad de Navarra, Pamplona, Spain.
    (11) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
    (12) Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain.
    (13) Department of Neumology, Clínica Universidad de Navarra, Pamplona, Spain.
    (14) Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.
    (15) Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

    Thorax 01 de ABRIL de 2019

  • 18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging

    Caresia Aroztegui AP (1), García Vicente AM (2), Alvarez Ruiz S (3), Delgado Bolton RC (4), Orcajo Rincon J (5), Garcia Garzon JR (6), de Arcocha Torres M (7), Garcia-Velloso MJ (8); Oncology Task Force of the Spanish Society of Nuclear Medicine and Molecular Imaging.

    (1) Department of Nuclear Medicine, Hospital Parc Taulí, Sabadell, Spain.
    (2) Department of Nuclear Medicine, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain.
    (3) Department of Nuclear Medicine, Hospital Universitario Miguel Servet, Zaragoza, Spain.
    (4) Department of Diagnostic Imaging and Nuclear Medicine, Hospital San Pedro-Centro de Investigación Biomédica de La Rioja (CIBIR), Logroño, Spain.
    (5) Department of Nuclear Medicine, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
    (6) PET/CT Unit, CETIR-ERESA, Esplugues de Llobregat, Spain.
    (7) Radiopharmacy Unit, Hospital Universitario Marques de Valdecilla, Santander, Spain.
    (8) Department of Nuclear Medicine, Clínica Universidad de Navarra, Pamplona, Spain.

    Tumour Biology 01 de OCTUBRE de 2017

  • 11C-Metionina-PET en el mieloma múltiple: un estudio combinado de dos instituciones diferentes

    Lapa C (1), Garcia-Velloso MJ (2), Lückerath K 1, Samnick S 1, Schreder M (3), Otero PR (2), Schmid JS 1, Herrmann K 1,4, Knop S 3, Buck AK (1), Einsele H (3), San-Miguel J (2), Kortüm KM (3). (1) University Hospital Würzburg, Department of Nuclear Medicine, Würzburg, Germany.
    (2) Clinica Universidad de Navarra, Center of Applied Medical Research, Navarra Institute for Health Research (CIMA). IDISNA, Pamplona, Spain.
    (3) University Hospital Würzburg, Department of Hematology and Oncology, Würzburg, Germany.
    (4) University Hospital Essen, Department of Nuclear Medicine, Essen, Germany.

    Theranostics 24 de JULIO de 2017

  • 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

    Cardoso F (1), van't Veer LJ (1), Bogaerts J (1), Slaets L (1), Viale G (1), Delaloge S (1), Pierga JY (1), Brain E (1), Causeret S (1), DeLorenzi M (1), Glas AM (1), Golfinopoulos V (1), Goulioti T (1), Knox S (1), Matos E (1), Meulemans B (1), Neijenhuis PA (1), Nitz U (1), Passalacqua R (1), Ravdin P (1), Rubio IT (1), Saghatchian M (1), Smilde TJ (1), Sotiriou C (1), Stork L (1), Straehle C (1), Thomas G (1), Thompson AM (1), van der Hoeven JM (1), Vuylsteke P(1), Bernards R (1), Tryfonidis K (1), Rutgers E (1), Piccart M (1); MINDACT Investigators.

    (1) From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (L.J.V.); European Organization for Research and Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - all in France; Swiss Institute of Bioinformatics and University of Lausanne, Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).

    The New England Journal Medicine 25 de AGOSTO de 2016

  • 2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia

    Soldevilla MM (1), Villanueva H (1), Bendandi M (2), Inoges S (3), López-Díaz de Cerio A (3), Pastor F (4).
    (1) CIMA, Program of Molecular Therapies, Aptamer Unit, Universidad de Navarra, Avenida Pio XII 55, 31008, Pamplona, Spain.
    (2) Ross University School of Medicine, PO Box 266 Roseau, Portsmouth, Dominica.
    (3) Clínica Universidad de Navarra, Avenida Pío XII, 36, 31008, Pamplona, Spain.
    (4) CIMA, Program of Molecular Therapies, Aptamer Unit, Universidad de Navarra, Avenida Pio XII 55, 31008, Pamplona, Spain 

    Biomaterials 01 de OCTUBRE de 2015

Anterior 1 2 3 Siguiente

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra